People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ocugen, Inc. | — | Biotechnology | Series B | $145.6M | $566.9M | 2016 |
| Nuron Biotech, Inc. | — | Biotechnology | Series B | $52.7M | $901.2M | 2012 |
Shankar Musunuri at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shankar Musunuri on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Johnson | 1 | 25 |
| Garheng Kong | 1 | 16 |
| Michael Lewis | 1 | 12 |
| Kevin Rakin | 1 | 7 |
| Patrick O'Donnell | 1 | 6 |
| Gregory B. Brown | 1 | 4 |
| Adam Gridley | 1 | 4 |
| Todd C. Davis | 1 | 3 |
| Peter Greenleaf | 1 | 3 |
| Kevin McArdle | 1 | 3 |
| Jonathan J. Lieber | 1 | 2 |
| Joshua Baltzell | 1 | 2 |
| David J. Gill | 1 | 2 |
| Martin Coyne | 1 | 2 |
| Manish Potti | 1 | 2 |
| Charles Kang | 1 | 2 |
| Ramesh Kumar | 1 | 2 |
| Frank Leo | 1 | 2 |
| John Zhang | 1 | 2 |
| Garheng Kong, M.D., Ph.D | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.